![]()
|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J Biol Chem, Vol. 275, Issue 19, 14013-14016, May 12, 2000
,
§,
From the Department of Molecular Biology and Applied Physiology,
Tohoku University School of Medicine, Aoba-ku, Sendai, Miyagi 980-8575, Japan,
Kondoh Differentiation Signaling Project, ERATO,
Japan Science and Technology Corporation (JST), 14 Yoshidakawaramachi,
Sakyo-ku, Kyoto 606-8305, Japan, and § Center for Molecular
and Developmental Biology, Graduate School of Science, Kyoto
University, Sakyo-ku, Kyoto 606-8502, Japan
| |
ABSTRACT |
|---|
|
|
|---|
Microphthalmia-associated transcription factor
(Mitf) plays a critical role in the development of neural crest-derived
melanocytes. Here, we show that exogenously added Wnt-3a protein, an
intercellular signaling molecule, up-regulates the expression of
endogenous melanocyte-specific Mitf (Mitf-M) mRNA in cultured
melanocytes. The melanocyte-specific promoter of the human
MITF gene (MITF-M promoter) contains a
functional LEF-1-binding site, which is bound in vitro by
LEF-1 and confers the preferential expression on a reporter gene in
melanocytes and melanoma cells, as judged by the transient transfection
assays. Moreover, the LEF-1-binding site is required for the
transactivation of a reporter gene by LEF-1, Microphthalmia-associated transcription factor
(Mitf),1 encoded by the mouse
Mitf locus, plays a critical role in the differentiation of
various cell types, including neural crest-derived melanocytes, bone
marrow-derived mast cells and osteoclasts, and optic cup-derived retinal pigment epithelium (RPE) (1-3). Mitf and its human
counterpart, MITF, contain a basic helix-loop-helix leucine zipper
structure, which is required for DNA binding and dimer formation. MITF
consists of at least five isoforms with distinct amino termini, called MITF-A, -B, -C, -H, and -M (4-6). The amino termini of these isoforms
are encoded by a separate first exons, and each exon 1 is under the
control of a unique promoter (6). Among these isoforms, MITF-M/Mitf-M
is exclusively expressed in melanocytes and melanoma cells of neural
crest origin (4, 5, 7). In fact, the 5'-flanking region of the first
exon, coding for the amino terminus of MITF-M, shows the
melanocyte-specific promoter function (8), here referred to as the
MITF-M promoter. In contrast, other MITF isoforms are widely
expressed in many cell types (4, 5).
MITF-M/Mitf-M efficiently transactivates the melanogenesis enzyme
genes, such as tyrosinase and tyrosinase-related
protein-1, in cultured cells (9-14) and can convert a fibroblast
cell line to the cells expressing tyrosinase and
tyrosinase-related protein-1 (15). The mutations in the
MITF/Mitf gene were found in patients with auditory
pigmentary syndromes such as Waardenburg syndrome type 2 (16-18), as
well as in many Mitf mutant mice (2). These affected
individuals mainly exhibit hypopigmentation and hearing impairment,
caused by the lack of pigment cells in the skin and inner ear.
Moreover, the MITF-M promoter is up-regulated by PAX3 (19),
a transcription factor with a paired-homeodomain, in which the gene is
responsible for Waardenburg syndrome types 1 and 3 (17). Moreover, the
essential requirement of Mitf-M in melanocyte development was verified
by the molecular lesion of the black-eyed white
Mitfmi-bw mice (20), which are characterized by a
completely white coat color, deafness, and normally pigmented RPE (21).
In Mitfmi-bw mice, the insertion of an L1
retrotransposable element in intron 3 lead to complete repression of
Mitf-M mRNA expression and to a reduction of Mitf-A and Mitf-H
mRNAs expression (20). Taken together, these results indicate that
MITF-M/Mitf-M is a key regulator of the melanocyte development but is
dispensable for RPE development. However, the mechanism of
differentiation of neural crest cells toward melanocytes is not well understood.
Wnt proteins, which are secreted cysteine-rich glycoproteins, have been
established as developmentally important signaling molecules (22).
Particularly, Wnt-1 and Wnt-3a are required for the expansion of neural
crest precursors (23, 24) and for determining the fate of neural crest
cells during early development (25). In fact, targeted disruption of
the Wnt-1 and Wnt-3a genes in the mouse causes
deficiency of neural crest derivatives, including melanocytes (24). On
the other hand, mutant mice lacking Wnt-1 or
Wnt-3a show no noticeable deficiency of neural crest
derivatives from the dorsal neural tube (26, 27). These results suggest a redundant role for Wnt-1 and Wnt-3a signaling in the differentiation of neural crest precursors. Wnt-3a is expressed in pluripotent ectoderm
cells of the primitive streak during gastrulation (27). The onset of
Wnt-3a expression is detected at embryonic day 7.5 (27), which precedes
the onset of Mitf expression in neural crest cells (9.5-10.5 days)
(28). These results suggest that Wnt-3a is a good candidate for
regulating the differentiation of neural crest cells toward
melanocytes. The signals evoked by Wnt proteins lead to intracellular
accumulation of Here, we show that exogenously added Wnt-3a protein induces endogenous
Mitf-M mRNA in cultured melanocytes. In addition, we identify the
functional LEF-1-binding site in the MITF-M promoter and
provide evidence that Wnt-3a signaling recruits Wnt-3a Conditioned Medium--
The mouse fibroblast L cells,
constitutively expressing mouse Wnt-3a cDNA, were seeded at a
density of 1 × 106 in a 94-mm dish containing a 1:1
mixture of Dulbecco's modified Eagle's medium and Ham's F12
supplemented with 10% fetal calf serum (30). After 3 days of culture,
cells were refed with fresh medium and incubated for 1 more day, and
the cultured media were collected as conditioned media, referred to as
Wnt3a/L-CM. Wnt3a/L-CM was estimated to contain about 400 ng/ml of
Wnt-3a protein (30). Conditioned media, neo/L-CM, were also prepared
from the cultures of control L cells that were stably transfected with
a vector plasmid as described previously (30).
Northern Blot Analysis--
Melan-a murine-immortalized
melanocytes, a gift from D. C. Bennett (31), were grown in minimum
essential medium supplemented with 10% fetal calf serum and 200 nM phorbol 12-myristate 13-acetate. Melan-a cells,
maintained in a 3.5-cm dish containing 1 ml of the medium, were treated
with Wnt3a/L-CM or neo/L-CM for 24 h. The final concentration of
Wnt-3a was about 40 ng/ml. Total RNA was prepared from the treated
Melan-a cells of two dishes and subjected to Northern blot analysis as
described previously (15). The ClaI/EcoRI DNA
fragment of human MITF cDNA (32) and glyceraldehyde 3'-phosphate
dehydrogenase cDNA (positions 601-1052) (33) were labeled with
[ Plasmid Preparation--
A wild-type reporter plasmid,
pGL3-MITF/M, was constructed as follows. The
BamHI/XhoI fragment containing the 2.2-kilobase pair human MITF-M pomoter was isolated from pHMIL1 (8) and ligated to pGL3-Basic (Promega), linearized by the digestion with SmaI and XhoI. Prior to ligation, the
BamHI site had been converted to a blunt end by a filling-in
reaction. A mutant construct, pGL3-MITF/M(m195), was constructed from
pGL3-MITF/M by the QuickChange site-directed mutagenesis kit
(Stratagene) according to the manufacturer's instructions. The mutant
primer used was the synthetic oligonucleotide (positions
Human LEF-1 cDNA, a gift from K. A. Jones (34), was subcloned
in the pRc/CMV eukaryotic expression vector (Invitrogen), yielding
pRc/CMV-LEF-1. A dominant-negative form of LEF-1, DNLEF-1, lacks the 26 amino acid residues near the amino terminus (amino acid positions
2-27); its cDNA was made by polymerase chain reaction and
subcloned in pRc/CMV, generating pRc/CMV-DNLEF-1. Electrophoretic Mobility Shift Assay (EMSA)--
LEF-1 protein
was produced from pRc/CMV-LEF-1 by in vitro
transcription/translation reaction using a TNT T7-coupled reticulocyte lysate system kit (Promega). The production of LEF-1 protein was assessed by electrophoresis of the translation products labeled with
[35S]methionine. The wild-type oligonucleotide of the
MITF promoter sequence from nucleotides Transfection and Luciferase Assay--
HeLa cells were grown in
minimum essential medium supplemented with 10% fetal calf serum.
HMV-II melanoma cells were grown in Ham's F12 medium supplemented with
10% fetal calf serum. HeLa cells were seeded at 60-80% confluency in
a 3.5-cm dish 18-24 h prior to transfection. Transfection was
performed by the calcium phosphate precipitation method (18). The
amount of DNA used for transfection was 6 µg, consisting of 0.5 µg
of each test plasmid and pCH110,
Melan-a cells were transfected by FuGene 6 transfection reagent (Roche
Molecular Biochemicals) according to the manufacturer's instructions.
The amount of DNA used for transfection was 1.5 µg, consisting of 0.5 µg of each test plasmid and pCH110, with pBluescript SK(+) as a
filler. After 4 h, Wnt3a/L-CM or neo/L-CM was added to each
culture medium of transfected Melan-a cells. Cells were then incubated
for 24 h and harvested.
To assess the hypothesis that Wnt signaling regulates the
expression of MITF-M/Mitf-M, we analyzed the effect of Wnt-3a protein on Mitf-M mRNA expression in cultured melanocytes. Accordingly, Melan-a immortalized melanocytes were treated with Wnt3a/L-CM containing Wnt-3a protein or neo/L-CM for 24 h (Fig.
1). The treatment with Wnt3a/L-CM
increased Mitf-M mRNA by 24 h (lane 1), whereas the
treatment with neo/L-CM did not (lane 2). Thus, Wnt-3a
induces the expression of endogenous Mitf-M mRNA, supporting the
notion that Wnt signaling is involved in melanocyte
differentiation.
-catenin, or their
combination. Exogenously added Wnt-3a protein also transactivates the
MITF-M promoter via the LEF-1-binding site; this activation
was abolished when a dominant-negative form of LEF-1 was coexpressed.
These results suggest that Wnt-3a signaling recruits
-catenin and
LEF-1 to the LEF-1-binding site of the MITF-M promoter.
Therefore, the present study identifies Mitf-M/MITF-M as a direct
target of Wnt signaling.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-catenin, a key downstream component of the Wnt
signaling pathway (22, 29).
-Catenin then activates the target genes
through interaction with a member of the LEF-1/TCF transcription
factors, containing a high mobility group domain. Thus, LEF-1/TCF
transcription factors mediate a nuclear response to Wnt signals.
-catenin and LEF-1
to the MITF-M promoter, which leads to increased
transcription from the MITF-M promoter. Therefore, the
present study shows a direct link between Wnt signaling and
Mitf-M/MITF-M expression.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-32P]dCTP using a BcaBEST labeling kit (Takara) and
were used as hybridization probes.
215 to
174) carrying the base changes at positions
196 and
195. Thus,
pGL3-MITF/M(m195) carries the GT nucleotides instead of the original TG
nucleotides at position
195 (8).
-Catenin cDNA
was synthesized by reverse-transcribed polymerase chain reaction and
subcloned in pRc/CMV, yielding pRc/CMV-
-catenin. TOPFLASH and
FOPFLASH, gifts from M. van de Wetering and H. Clevers (35), contain
the LEF-1 responsive elements and the mutated LEF-1 responsive elements, respectively.
215 to
174
(5'-CTGACAGTGAGTTTGACTTTGATAGCTCGTCACTTAAAAAGG-3'/3'-GACTGTCACTCAAACTGAAACTATCGAGCAGTGAATTTTTCC-5') was end-labeled with [
-32P]ATP and T4
polynucleotide kinase and used as a probe. EMSA was carried out as
described previously (18).
-galactosidase expression vector
under control of SV40 early promoter as an internal control, and
pBluescript SK(+) as a filler. Transfection was also carried out in
HMV-II melanoma cells as described above. After 24 h, transfected
cells were harvested, and the activities of luciferase and
-galactosidase were measured as described previously (13).
Luciferase activity was normalized by
-galactosidase activity.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (54K):
[in a new window]
Fig. 1.
Induction of Mitf mRNA
expression in melanocytes by Wnt-3a protein. Shown is an
autoradiogram of the Northern blot hybridized with MITF cDNA. Each
lane contained 7 µg of RNA prepared from Melan-a cells
treated for 24 h with Wnt3a/L-CM containing Wnt-3a (lane
1) or neo/L-CM (lane 2). The untreated control (treated
for 0 h) is also shown (lane 3). Glyceraldehyde
3'-phosphate dehydrogenase (G3PDH) mRNA was detected as
an internal control. 18 and 28 S ribosomal RNAs are shown by
arrowheads.
Wnt signaling activates the target genes through the interaction of
-catenin and a member of the LEF-1/TCF transcription factors. The
consensus DNA sequence recognized by LEF-1/TCF transcription factors is
CTTTGA/TA/T (29), and the MITF-M promoter contains a
putative LEF-1/TCF-binding site, CTTTGAT (positions
199 to
193),
which agrees with the consensus sequence (Fig.
2A). The same sequence motif
is conserved at a similar position in the mouse Mitf-M
promoter.2 To assess the
function of the putative LEF-1/TCF-binding site in the
MITF-M promoter, we compared the expression levels of
pGL3-MITF/M in HMV-II human melanoma cells with those of
pGL3-MITF/M(m195), containing the altered LEF-1/TCF site, CTTGTAT (Fig.
2B). These base changes were expected to reduce the
MITF-M promoter activity, because the Wnt signaling pathway
is activated in many melanoma cells due to
-catenin mutation (36).
In fact, the expression level of pGL3-MITF/M(m195) was lower than that
of pGL3-MITF/M, whereas the expression levels of these two constructs
were similarly lower in HeLa cervical cancer cells. These results
suggest that the CTTTGAT motif is involved in MITF-M
promoter activity in melanoma cells. The significant luciferase
activity detected with pGL3-MITF/M(m195) in melanoma cells may be due
to the presence of other melanocyte-specific enhancers present in the
MITF-M promoter.
|
We then performed cotransfection assays in HeLa cervical cancer cells
to test the possibility that the LEF-1/TCF family is involved in
regulation of the MITF-M promoter (Fig. 2C).
Expression of either LEF-1 or
-catenin significantly increased the
luciferase activity under the control of the MITF-M
promoter. The coexpression of
-catenin and LEF-1 synergistically
increased the luciferase activity, which was higher than the degree of
activation caused by LEF-1 or
-catenin. In contrast, the
introduction of mutation at the putative LEF-1 site completely
inhibited the increase in luciferase activity caused by LEF-1,
-catenin, or their combination (Fig. 2C). These results
suggest that the CTTTGAT motif of the MITF-M promoter
represents a functional LEF-1-binding site.
To confirm whether LEF-1 protein binds to the CTTTGAT motif of the
MITF-M promoter, we carried out EMSA. The in
vitro translation of LEF-1 mRNA was confirmed by
autoradiography of 35S-labeled LEF-1 protein (data not
shown). The synthetic LEF-1-binding site was specifically bound by the
in vitro translated LEF-1 protein (Fig.
3, lane 1). The formation of
this complex was inhibited by competitor oligonucleotide containing the
CTTTGAT motif but not by the mutant oligonucleotide containing the
CTTGTAT motif (lanes 2 and 3). Taken together,
these results indicate that LEF-1 recognizes the CTTTGAT motif of the
MITF-M promoter. These results are consistent in part with
the recent report showing that the LEF-1/TCF-binding sites of the
promoter region of the Nacre, a zebrafish homolog of
MITF, is required for pigment cell-specific expression of a
reporter gene in vivo (37).
|
Finally, we assessed the effects of Wnt-3a protein on the
MITF-M promoter activity in Melan-a cells (Fig.
4). In this series of experiments,
Melan-a immortalized melanocytes were chosen because this cell line was
more sensitive to Wnt-3a treatment than HMV-II melanoma cells, as
judged by transient expression assays with the test plasmid TOPFLASH,
containing multiple LEF-1 responsive elements (data not shown). Such a
difference in sensitivity to Wnt-3a suggests that a component(s) of the
Wnt signaling pathway, such as
-catenin, may be constitutively
activated in HMV-II melanoma cells.
|
Melan-a cells were transfected with pGL3-MITF/M or pGL3-MITF/M(m195)
and then treated with either Wnt3a/L-CM or neo/L-CM. Wnt3a/L-CM
increased the expression of pGL3-MITF/M by about 2.5-fold. To confirm
that this increase was dependent on Wnt signaling, we cotransfected the
expression plasmid of a dominant-negative form of LEF-1,
pRc/CMV-DNLEF-1. The dominant-negative LEF-1 lacks the amino-terminal
-catenin interaction domain and is expected to inhibit Wnt
signaling. The observed activation by Wnt3a/L-CM was completely
inhibited when the dominant-negative LEF-1 was coexpressed.
Furthermore, the expression level of pGL3-MITF/M(m195) was lower than
that of a wild-type construct, pGL3-MITF/M, and was not significantly
increased by treatment with Wnt3a/L-CM. These results indicate that the
LEF-1 site is necessary and sufficient for the activation of the
MITF-M promoter by Wnt-3a signaling. The data all support
the interpretation of a direct effect by Wnt-3a, but there is a
possibility that a certain factor other than Wnt-3a in the conditioned
medium from the Wnt-3a transfectants could contribute to the
LEF-1-dependent activation. Further study with Wnt-3a
neutralizing antibodies will be required to address this issue.
The MITF-M promoter is functional exclusively in
melanocyte-lineage cells (6, 8) and is up-regulated via the separate cis-acting elements by PAX3 (19) and by
-melanocyte-stimulating hormone signaling (38) (see Fig.
2A). Here, we provide evidence that Wnt-3a signal activates
the MITF-M promoter through the LEF-1-binding site. Thus,
multiple signals appear to converge on the MITF-M promoter,
leading to the up-regulation of MITF-M expression, a key regulator for
the melanogenesis enzyme genes. The expression levels of Pax3 mRNA
were reduced in the double knock-out mouse of the Wnt-1 and
Wnt-3a genes (24). It is therefore conceivable that Wnt
signals may also up-regulate Mitf-M/MITF-M expression through Pax3.
In summary, Wnt-3a protein induces Mitf-M mRNA expression in
melanocytes and activates the MITF-M promoter by recruiting
LEF-1 and
-catenin to the LEF-1-binding site. Thus,
MITF-M/Mitf-M is a direct target gene of Wnt signaling in
humans and mice.
| |
ACKNOWLEDGEMENTS |
|---|
We thank D. Bennett for Melan-a cells, K. A. Jones for LEF-1 cDNA, and M. van de Wetering and H. Clevers for pTOPFLASH and pFOPFLASH.
| |
FOOTNOTES |
|---|
* This work was supported in part by grants-in-aid for scientific research (B), for exploratory research, and for encouragement of young scientist (to K. Y.) from the Ministry of Education, Science, Sports and Culture of Japan. This work was also supported in part by the Nakatomi Foundation and the Kao Foundation for Arts and Sciences.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed. Tel.: 81-22-717-8117; Fax: 81-22-717-8118; E-mail: shibahar@mail.cc.tohoku.ac.jp.
Published, JBC Papers in Press, March 15, 2000, DOI 10.1074/jbc.C000113200
2 K. Takeda, K. Yasumoto, K. Watanabe, T. Udono, H. Saito, K. Takahashi, and S. Shibahara, unpublished observations.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: Mitf, microphthalmia-associated transcription factor; Mitf-M, melanocyte-specific Mitf; EMSA, electrophoretic mobility shift assay; RPE, retinal pigment epithelium; CMV, cytomegalovirus.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrimsson, E., Copeland, N. G., Jenkins, N. A., and Arnheiter, H. (1993) Cell 74, 395-404 |
| 2. | Steingrimsson, E., Moore, K. J., Lamoreux, M. L., Ferre, D. A. A. R., Burley, S. K., Zimring, D. C., Skow, L. C., Hodgkinson, C. A., Arnheiter, H., Copeland, N. G., et al.. (1994) Nat. Genet. 8, 256-263 |
| 3. | Stechschulte, D. J., Sharma, R., Dileepan, K. N., Simpson, K. M., Aggarwal, N., Clancy, J., Jr., and Jilka, R. L. (1987) J. Cell. Physiol. 132, 565-570 |
| 4. | Amae, S., Fuse, N., Yasumoto, K., Sato, S., Yajima, I., Yamamoto, H., Udono, T., Durlu, Y. K., Tamai, M., Takahashi, K., and Shibahara, S. (1998) Biochem. Biophys. Res. Commun. 247, 710-715 |
| 5. | Fuse, N., Yasumoto, K., Takeda, K., Amae, S., Yoshizawa, M., Udono, T., Takahashi, K., Tamai, M., Tomita, Y., Tachibana, M., and Shibahara, S. (1999) J. Biochem. (Tokyo) 126, 1043-1051 |
| 6. | Udono T., Yasumoto, K., Takeda K., Amae S., Watanabe K., Saito H., Fuse N., Tachibana M., Takahashi K., Tamai M., and Shibahara S. (2000) Biochim. Biophys. Acta, in press |
| 7. | Yasumoto, K., Amae, S., Udono, T., Fuse, N., Takeda, K., and Shibahara, S. (1998) Pigm. Cell Res. 11, 329-336 |
| 8. | Fuse, N., Yasumoto, K., Suzuki, H., Takahashi, K., and Shibahara, S. (1996) Biochem. Biophys. Res. Commun. 219, 702-707 |
| 9. | Hemesath, T. J., Steingrimsson, E., McGill, G., Hansen, M. J., Vaught, J., Hodgkinson, C. A., Arnheiter, H., Copeland, N. G., Jenkins, N. A., and Fisher, D. E. (1994) Genes Dev. 8, 2770-2780 |
| 10. | Aksan, I., and Goding, C. R. (1998) Mol. Cell. Biol. 18, 6930-6938 |
| 11. | Bentley, N. J., Eisen, T., and Goding, C. R. (1994) Mol. Cell. Biol. 14, 7996-8006 |
| 12. | Yasumoto, K., Yokoyama, K., Shibata, K., Tomita, Y., and Shibahara, S. (1994) Mol. Cell. Biol. 14, 8058-8070 |
| 13. | Yasumoto, K., Mahalingam, H., Suzuki, H., Yoshizawa, M., and Yokoyama, K. (1995) J. Biochem. (Tokyo) 118, 874-881 |
| 14. | Yasumoto, K., Yokoyama, K., Takahashi, K., Tomita, Y., and Shibahara, S. (1997) J. Biol. Chem. 272, 503-509 |
| 15. | Tachibana, M., Takeda, K., Nobukuni, Y., Urabe, K., Long, J. E., Meyers, K. A., Aaronson, S. A., and Miki, T. (1996) Nat. Genet. 14, 50-54 |
| 16. | Tassabehji, M., Newton, V. E., and Read, A. P. (1994) Nat. Genet. 8, 251-255 |
| 17. | Tassabehji, M., Newton, V. E., Liu, X. Z., Brady, A., Donnai, D., Krajewska-Walasek, M., Murday, V., Norman, A., Obersztyn, E., Reardon, W., et al.. (1995) Hum. Mol. Genet. 4, 2131-2137 |
| 18. | Nobukuni, Y., Watanabe, A., Takeda, K., Skarka, H., and Tachibana, M. (1996) Am. J. Hum. Genet. 59, 76-83 |
| 19. | Watanabe, A., Takeda, K., Ploplis, B., and Tachibana, M. (1998) Nat. Genet. 18, 283-286 |
| 20. | Yajima, I., Sato, S., Kimura, T., Yasumoto, K., Shibahara, S., Goding, C. R., and Yamamoto, H. (1999) Hum. Mol. Genet. 8, 1431-1441 |
| 21. | Motohashi, H., Hozawa, K., Oshima, T., Takeuchi, T., and Takasaka, T. (1994) Hear. Res. 80, 10-20 |
| 22. | Cadigan, K. M., and Nusse, R. (1997) Genes Dev. 11, 3286-3305 |
| 23. | Saint-Jeannet, J. P., He, X., Varmus, H. E., and Dawid, I. B. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 13713-13718 |
| 24. | Ikeya, M., Lee, S. M., Johnson, J. E., McMahon, A. P., and Takada, S. (1997) Nature 389, 966-970 |
| 25. | Dorsky, R. I., Moon, R. T., and Raible, D. W. (1998) Nature 396, 370-373 |
| 26. | Thomas, K. R., and Capecchi, M. R. (1990) Nature 346, 847-850 |
| 27. | Takada, S., Stark, K. L., Shea, M. J., Vassileva, G., McMahon, J. A., and McMahon, A. P. (1994) Genes Dev. 8, 174-189 |
| 28. | Nakayama, A., Nguyen, M. T., Chen, C. C., Opdecamp, K., Hodgkinson, C. A., and Arnheiter, H. (1998) Mech. Dev. 70, 155-166 |
| 29. | Eastman, Q., and Grosschedl, R. (1999) Curr. Opin. Cell Biol. 11, 233-240 |
| 30. | Shibamoto, S., Higano, K., Takada, R., Ito, F., Takeichi, M., and Takada, S. (1998) Genes Cells 3, 659-670 |
| 31. | Bennett, D. C., Cooper, P. J., and Hart, I. R. (1987) Int. J. Cancer 39, 414-418 |
| 32. | Tachibana, M., Perez-Jurado, L. A., Nakayama, A., Hodgkinson, C. A., Li, X., Schneider, M., Miki, T., Fex, J., Francke, U., and Arnheiter, H. (1994) Hum. Mol. Genet. 3, 553-557 |
| 33. | Ercolani, L., Florence, B., Denaro, M., and Alexander, M. (1988) J. Biol. Chem. 263, 15335-15341 |
| 34. | Waterman, M. L., Fischer, W. H., and Jones, K. A. (1991) Genes Dev. 5, 656-669 |
| 35. | van de Wetering, M., Cavallo, R., Dooijes, D., van Beest, M., van Es, J., Loureiro, J., Ypma, A., Hursh, D., Jones, T., Bejsovec, A., Peifer, M., Mortin, M., and Clevers, H. (1997) Cell 88, 789-799 |
| 36. | Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., and Polakis, P. (1997) Science 275, 1790-1792 |
| 37. | Dorsky, R. I., Raible, D. W., and Moon, R. T. (2000) Genes Dev. 14, 158-162 |
| 38. | Price, E. R., Horstmann, M. A., Wells, A. G., Weilbaecher, K. N., Takemoto, C. M., Landis, M. W., and Fisher, D. E. (1998) J. Biol. Chem. 273, 33042-33047 |
This article has been cited by other articles:
![]() |
I. Matera, D. E. Watkins-Chow, S. K. Loftus, L. Hou, A. Incao, D. L. Silver, C. Rivas, E. C. Elliott, L. L. Baxter, and W. J. Pavan A sensitized mutagenesis screen identifies Gli3 as a modifier of Sox10 neurocristopathy Hum. Mol. Genet., July 15, 2008; 17(14): 2118 - 2131. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. N. Dynek, S. M. Chan, J. Liu, J. Zha, W. J. Fairbrother, and D. Vucic Microphthalmia-Associated Transcription Factor Is a Critical Transcriptional Regulator of Melanoma Inhibitor of Apoptosis in Melanomas Cancer Res., May 1, 2008; 68(9): 3124 - 3132. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Delmas, F. Beermann, S. Martinozzi, S. Carreira, J. Ackermann, M. Kumasaka, L. Denat, J. Goodall, F. Luciani, A. Viros, et al. beta-Catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development Genes & Dev., November 15, 2007; 21(22): 2923 - 2935. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takeda, T. Adachi, F. Han, S. Yokoyama, H. Yamamoto, W. Hida, and S. Shibahara Augmented Chemosensitivity in Black-Eyed White Mitf mi-bw Mice, Lacking Melanocytes J. Biochem., March 1, 2007; 141(3): 327 - 333. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schepsky, K. Bruser, G. J. Gunnarsson, J. Goodall, J. H. Hallsson, C. R. Goding, E. Steingrimsson, and A. Hecht The Microphthalmia-Associated Transcription Factor Mitf Interacts with {beta}-Catenin To Determine Target Gene Expression Mol. Cell. Biol., December 1, 2006; 26(23): 8914 - 8927. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Carney, K. A. Dutton, E. Greenhill, M. Delfino-Machin, P. Dufourcq, P. Blader, and R. N. Kelsh A direct role for Sox10 in specification of neural crest-derived sensory neurons Development, December 1, 2006; 133(23): 4619 - 4630. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Yokoyama, K. Takeda, and S. Shibahara Functional Difference of the SOX10 Mutant Proteins Responsible for the Phenotypic Variability in Auditory-Pigmentary Disorders J. Biochem., October 1, 2006; 140(4): 491 - 499. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chin, L. A. Garraway, and D. E. Fisher Malignant melanoma: genetics and therapeutics in the genomic era. Genes & Dev., August 15, 2006; 20(16): 2149 - 2182. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Goding and F. L. Meyskens Jr. Microphthalmic-Associated Transcription Factor Integrates Melanocyte Biology and Melanoma Progression Clin. Cancer Res., February 15, 2006; 12(4): 1069 - 1073. [Full Text] [PDF] |
||||
![]() |
K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, C. Kuo, H.-J. Wang, R. Milford, D. L. Morton, et al. Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients Clin. Cancer Res., February 15, 2006; 12(4): 1137 - 1143. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Voigt and N. Papalopulu A dominant-negative form of the E3 ubiquitin ligase Cullin-1 disrupts the correct allocation of cell fate in the neural crest lineage Development, February 1, 2006; 133(3): 559 - 568. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Osawa, G. Egawa, S.-S. Mak, M. Moriyama, R. Freter, S. Yonetani, F. Beermann, and S.-I. Nishikawa Molecular characterization of melanocyte stem cells in their niche Development, December 15, 2005; 132(24): 5589 - 5599. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Sommer Checkpoints of Melanocyte Stem Cell Development Sci. Signal., August 23, 2005; 2005(298): pe42 - pe42. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ji and O. M. Andrisani High-Level Activation of Cyclic AMP Signaling Attenuates Bone Morphogenetic Protein 2-Induced Sympathoadrenal Lineage Development and Promotes Melanogenesis in Neural Crest Cultures Mol. Cell. Biol., June 15, 2005; 25(12): 5134 - 5145. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yamaguchi, S. Itami, H. Watabe, K.-i. Yasumoto, Z. A. Abdel-Malek, T. Kubo, F. Rouzaud, A. Tanemura, K. Yoshikawa, and V. J. Hearing Mesenchymal-epithelial interactions in the skin: increased expression of dickkopf1 by palmoplantar fibroblasts inhibits melanocyte growth and differentiation J. Cell Biol., April 26, 2004; 165(2): 275 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Goodall, S. Martinozzi, T. J. Dexter, D. Champeval, S. Carreira, L. Larue, and C. R. Goding Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by {beta}-Catenin Mol. Cell. Biol., April 1, 2004; 24(7): 2915 - 2922. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Lewis, J. Bonner, M. Modrell, J. W. Ragland, R. T. Moon, R. I. Dorsky, and D. W. Raible Reiterated Wnt signaling during zebrafish neural crest development Development, March 15, 2004; 131(6): 1299 - 1308. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Doglioni, S. Piccinin, S. Demontis, M. G. Cangi, L. Pecciarini, C. Chiarelli, M. Armellin, T. Vukosavljevic, M. Boiocchi, and R. Maestro Alterations of {beta}-Catenin Pathway in Non-Melanoma Skin Tumors: Loss of {alpha}-ABC Nuclear Reactivity Correlates with the Presence of {beta}-Catenin Gene Mutation Am. J. Pathol., December 1, 2003; 163(6): 2277 - 2287. [Abstract] [Full Text] |
||||
![]() |
W. E. Huber, E. R. Price, H. R. Widlund, J. Du, I. J. Davis, M. Wegner, and D. E. Fisher A Tissue-restricted cAMP Transcriptional Response: SOX10 MODULATES {alpha}-MELANOCYTE-STIMULATING HORMONE-TRIGGERED EXPRESSION OF MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR IN MELANOCYTES J. Biol. Chem., November 14, 2003; 278(46): 45224 - 45230. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Pham, T Milovanovic, R J Barr, T Truong, and R F Holcombe Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features Mol. Pathol., October 1, 2003; 56(5): 280 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. J. Davis, B.-L. Hsi, J. D. Arroyo, S. O. Vargas, Y. A. Yeh, G. Motyckova, P. Valencia, A. R. Perez-Atayde, P. Argani, M. Ladanyi, et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation PNAS, May 13, 2003; 100(10): 6051 - 6056. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hari, V. Brault, M. Kleber, H.-Y. Lee, F. Ille, R. Leimeroth, C. Paratore, U. Suter, R. Kemler, and L. Sommer Lineage-specific requirements of {beta}-catenin in neural crest development J. Cell Biol., December 9, 2002; 159(5): 867 - 880. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-X. Jin, H. Kishi, X.-C. Wei, T. Matsuda, S. Saito, and A. Muraguchi Lymphoid Enhancer-Binding Factor-1 Binds and Activates the Recombination-Activating Gene-2 Promoter Together with c-Myb and Pax-5 in Immature B Cells J. Immunol., October 1, 2002; 169(7): 3783 - 3792. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R. Widlund, M. A. Horstmann, E. R. Price, J. Cui, S. L. Lessnick, M. Wu, X. He, and D. E. Fisher {beta}-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor J. Cell Biol., September 16, 2002; 158(6): 1079 - 1087. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Khaled, L. Larribere, K. Bille, E. Aberdam, J.-P. Ortonne, R. Ballotti, and C. Bertolotto Glycogen Synthase Kinase 3beta Is Activated by cAMP and Plays an Active Role in the Regulation of Melanogenesis J. Biol. Chem., September 6, 2002; 277(37): 33690 - 33697. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Filali, N. Cheng, D. Abbott, V. Leontiev, and J. F. Engelhardt Wnt-3A/beta -Catenin Signaling Induces Transcription from the LEF-1 Promoter J. Biol. Chem., August 30, 2002; 277(36): 33398 - 33410. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Saito, K.-i. Yasumoto, K. Takeda, K. Takahashi, A. Fukuzaki, S. Orikasa, and S. Shibahara Melanocyte-specific Microphthalmia-associated Transcription Factor Isoform Activates Its Own Gene Promoter through Physical Interaction with Lymphoid-enhancing Factor 1 J. Biol. Chem., August 2, 2002; 277(32): 28787 - 28794. [Abstract] [Full Text] [PDF] |
||||
|
|